Back to News
Market Impact: 0.2
Kiniksa Pharmaceuticals International Average Price Target Raised 13.15% to $111.62
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The average one-year analyst price target for Kiniksa Pharmaceuticals International (NASDAQGS:KNSA) was revised to $111.62 per share, up 13.15% from the prior $98.65 estimate dated October 20, 2026. The figures represent aggregate analyst targets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Apple reports after the bell. Options traders expect a big move
- Why is Apple stock falling afterhours today?
- Mizuho lowers Lumentum stock price target on Marvell acquisition